PCI-24781

PCI-24781 is a broad-spectrum phenyl hydroxamic acid HDAC inhibitor currently being evaluated in phase I clinical trials in patients with neoplastic disease. The substance is a specific inhibitor of multiple HDAC isoforms (HDAC2, HDAC3/SMRT, HDAC6, HDAC8, HDAC10) that potently inhibits tumor growth in vivo with acceptable toxicity.

Synonyms: CRA-02478; CRA024781; CRA-024781
Technical Data: Molecular Weight - 397.43; Molecular formula - C21H23N3O5; CAS No - 783355-60-2

Ordering Information: Product Number - EC-000.2348; Price and Availability: Inquire This product is also available to buy in bulk quantities.

Related Products: Suberoylanilide Hydroxamic Acid; MS-275 (Entinostat); CI-994 (Tacedinaline); BML-210; M344; MGCD0103 (Mocetinostat); PXD101 (Belinostat); LBH-589 (Panobinostat); Tubastatin A; Scriptaid; NSC 3852; NCH 51; HNHA; BML-281; CBHA; Salermide; Pimelic Diphenylamide; ITF2357 (Givinostat); APHA Compound 8; Droxinostat; SB939.

References:
1. Adimoolam S, Sirisawad M, Chen J, et al. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7.
2. Joseph J. Buggy, Z. Alexander Cao, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther May 2006 5; 1309.